Launch of myLotus app in China

RNS Number : 3282F
Concepta PLC
20 February 2018
 

20 February 2018

 

Concepta plc

("Concepta" or the "Company")

 

Launch of myLotus app in China

 

Concepta plc (AIM: CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed an agreement with Beijing Jiayou Ltd, ("AppInChina") to manage the distribution of its new myLotus app on Android systems throughout China.

 

The free app, which allows women to monitor and track fertility, can be used either as an individual fertility tracker or in conjunction with the myLotus monitor.

 

Through AppInChina, Concepta will focus on distribution of the app through the top 5 Chinese Android app stores, which between them have a market share of around 75.7%* of the Android app market. This includes Tencent's Myapp, the leading Chinese app store, which holds a 25.1%* market share of the Android app distribution coverage in China.

 

In addition, the myLotus app is also currently available on the Chinese iOS app store, which has a 13% smartphone market share in China.

 

Erik Henau, CEO of Concepta commented: "The myLotus app is an extremely useful resource for women trying to conceive. Not only is it effective as a stand-alone resource, but in conjunction with our myLotus meter, it is a powerful tool to allow women with unexplained infertility to conceive naturally. It enables women who are struggling to conceive to monitor their ovulation cycle more effectively than standard home testing kits. The combination of both the app and the myLotus meter will enhance the consumer experience and the product proposition, as well as increasing awareness of the product."

 

"As the only app with a direct link to qualitative and quantitative results of a woman's personal hormone levels, it provides women with a platform to build an accurate conception diary, which will assist them and their partner during the process of conception."

 

* Newzoo - "Top 10 android app stores" https://newzoo.com/insights/rankings/top-10-android-app-stores-china/ 

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

 

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and hCG* hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFKCDBDBKBCBD
UK 100

Latest directors dealings